Breaking Research suggests Bergamet helps NAFLD
Research on bergamot extract continues to show its efficacy in managing metabolic sysdrome and non alcoholic fatty liver disease.
… the extract of bergamot juice rich in polyphenols, reduces both cholesterol, triglycerides and glucose in patients suffering from Metabolic Syndrome
From the report:
The occurrence of Metabolic Syndrome (MS) represents an independent risk factor for developing cardiovascular disease states in patients suffering from type 2 diabetes mellitus. Moreover, both the size of LDL particles and liver dysfunction identified as non alcoholic fatty liver disease (NAFLD) represent important biomarkers for the development of cardiometabolic risk in patients with MS. Here we studied the effect of bergamot polyphenolic fraction (BPF) in patients with MS and NAFLD. 107 patients were enrolled at the San Raffaele IRCCS (Rome).
All of them showed ul- trasonografic evidences of NAFLD and at least three out of five previous identified criteria for the diagnosis of MS. Patients were divided into two groups: one receiving placebo and the second re- ceiving BPF 650 mg twice a day for 120 consecutive days. In the group receiving BPF 650 mg twice a day, a significant reduction of fasting plasma glucose, serum LDL cholesterol and triglycerides alongside with an increase of HDL cholesterol was found. This effect was accompanied by signifi- cant reduction of both ultrasonographic and metabolic biomarkers of NAFLD. Moreover, a signifi- cant reduction of small dense LDL particles, as detected via proton NMR Spectroscopy, was found after BPF treatment.
In conclusion, our data confirm the beneficial effect of bergamot-extract in patients with MS an effect highlighted by significant reduction of small dense LDL particles and by improvement of NAFLD biomarkers. This suggests a potential preventive role of bergamot deriva- tives in reducing cardiometabolic risk.
